HIV vaccine efficacy and immune correlates of risk

Current HIV Research

Volumn 11, Issue 6, 2013, Pages 450-463

  O'Connell, Robert J ^a   Excler, Jean Louis ^b  

^a ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^b HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

Author keywords

Efficacy trial; HIV; Immune correlates; Prime boost; V2 antibodies; Vaccine

Indexed keywords

AIDSVAX B/E VACCINE; ALVAC HIV VCP VACCINE; GAMMA INTERFERON; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MRKAD5 VACCINE; UNCLASSIFIED DRUG; VRC HIVADV016 00 VP VACCINE; VRC HIVDNA016 00 VP VACCINE;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CD4 LYMPHOCYTE COUNT; CROSS REACTION; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; GENETIC POLYMORPHISM; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION RISK; INNATE IMMUNITY; LICENCE; MEMORY CELL; NONHUMAN; PHAGOCYTOSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); SEXUAL TRANSMISSION; VACCINATION; VIRUS LOAD;

AIDS VACCINES; ANIMALS; CLINICAL TRIALS AS TOPIC; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS;

EID: 84894102462     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/1570162x113116660052     Document Type: Article

References (138)

1. UNAIDS Report on the Global AIDS Epidemic 2012.
2. Wamai RG, Morris BJ, Bailis SA, et al. Male circumcision for HIV prevention: current evidence and implementation in sub-Saharan Africa. J Int AIDS Soc 2011; 14: 49.
3. Granich R, Gupta S, Suthar AB, et al. Antiretrovirals therapy in Prevention of HIV and TB: Update on Current Research Efforts. Curr HIV Res 2011; 9: 446-69.
4. Kim SC, Becker S, Dieffenbach C, et al. Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunities. J Int AIDS Soc 2010; 13: 24.
5. Granich R, Lo YR, Suthar A, et al. Harnessing the Prevention Benefits of Antiretroviral Treatment to Address HIV and Tuberculosis. Curr HIV Res 2011; 9: 355-66.
6. Krakower D, Mayer KH. Promising prevention approaches: tenofovir gel and prophylactic use of antiretroviral medications. Curr HIV/AIDS Rep 2011; 8: 241-8.
7. Chi BH, Adler MR, Bolu O, et al. Progress, challenges, and new opportunities for the prevention of mother-to-child transmission of HIV under the US President's Emergency Plan for AIDS Relief. J Acquir Immune Defic Syndr 2012; 60 Suppl 3: S78-S87.
8. Koff WC, Burton DR, Johnson PR, et al. Accelerating next- generation vaccine development for global disease prevention. Science 2013; 340: 1232910.
9. Kim JH, Rerks-Ngarm S, Excler JL, et al. HIV vaccines: lessons learned and the way forward. Curr Opin HIV AIDS 2010; 5: 428-34.
10. Koff WC. HIV vaccine development: Challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem. Vaccine 2012; 30: 4310-5.
11. O'Connell RJ, Kim JH, Corey L, et al. Human Immunodeficiency Virus Vaccine Trials. Cold Spring Harb Perspect Med 2012; 2: a007351.
12. Haynes BF, McElrath MJ. Progress in HIV-1 vaccine development. Curr Opin HIV AIDS 2013; 8: 326-32.
13. Excler JL, Tomaras GD, Russell ND. Novel directions in HIV-1 vaccines revealed from clinical trials. Curr Opin HIV AIDS 2013; 8: 420-30.
14. Barouch DH, Liu J, Li H, et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012; 482: 89-93.
15. Lynch RM, Yamamoto T, McDermott AB. HIV vaccine research and discovery in the nonhuman primates model: a unified theory in acquisition prevention and control of SIV infection. Curr Opin HIV AIDS 2013; 8: 288-94.
16. McMichael AJ, Borrow P, Tomaras GD, et al. The immune response during acute HIV-1 infection: Clues for vaccine development. Nat Rev Immunol 2010; 10: 11-23.
17. Qin L, Gilbert PB, Corey L, et al. A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis 2007; 196: 1304-12.
18. Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 2008; 47: 401-9.
19. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010; 17: 1055-65.
20. FDA. Guidance for Industry for the Evaluation of Combination Vaccines for Preventable Diseases: Production, Testing, and Clinical Studies, 1997, U.S. Department of Health and Human Services: Rockville, MD.
21. Plotkin SA, Gilbert PB. Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis 2012; 54: 1615-7.
22. Plotkin SA, Plotkin SL. The development of vaccines: how the past led to the future. Nat Rev Microbiol 2011; 9: 889-93.
23. Thakur A, Pedersen LE, Jungersen G. Immune markers and correlates of protection for vaccine induced immune responses. Vaccine 2012; 30: 4907-20.
24. Zinkernagel RM, Hengartner H. Protective 'immunity' by pre-existent neutralizing antibody titers and preactivated T cells but not by so-called 'immunological memory'. Immunol Rev 2006; 211: 310-9.
25. Fletcher HA. Correlates of immune protection from tuberculosis. Curr Mol Med 2007; 7: 319-25.
26. Levin MJ, Oxman MN, Zhang JH, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 2008; 197: 825-35.
27. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. N Engl J Med 2009; 361: 1-12.
28. Gilbert PB, Berger JO, Stablein D, et al. Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials. J Infect Dis 2011; 203: 969-75.
29. Robb ML, Rerks-Ngarm S, Nitayaphan S, et al. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis 2012; 12: 531-7.
30. Lee D, Graham BS, Chiu YL, et al. Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160. J Infect Dis 2004; 190: 903-7.
31. Rerks-Ngarm S, Paris RM, Chunsutthiwat S, et al. Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX(R) B/E. J Infect Dis 2013; 207: 1195-205.
32. Whitney JB, Luedemann C, Hraber P, et al. T-cell vaccination reduces simian immunodeficiency virus levels in semen. J Virol 2009; 83: 10840-3.
33. Pitisuttithum P, Rerks-Ngarm S, Bussaratid V, et al. Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand. PLoS One 2011; 6: e27837.
34. de Souza MS, Ratto-Kim S, Chuenarom W, et al. The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol 2012; 188: 5166-76.
35. Montefiori DC, Karnasuta C, Huang Y, et al. Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials. J Infect Dis 2012; 206: 431-41.
36. Paris R, Bejrachandra S, Thongcharoen P, et al. HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX(®) B/E. Vaccine 2012; 30: 832-6.
37. Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366: 1275-86.
38. Griffiss JM. Bactericidal activity of meningococcal antisera. Blocking by IgA of lytic antibody in human convalescent sera. J Immunol 1975; 114: 1779-84.
39. Mathew GD, Qualtiere LF, Neel HB III, et al. IgA antibody, antibody-dependent cellular cytotoxicity and prognosis in patients with nasopharyngeal carcinoma. Int J Cancer 1981; 27: 175-80.
40. Nikolova EB, Russell MW. Dual function of human IgA antibodies: inhibition of phagocytosis in circulating neutrophils and enhancement of responses in IL-8-stimulated cells. J Leukoc Biol 1995; 57: 875-82.
41. Ferrari G, Pollara J, Kozink D, et al. An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. J Virol 2011; 85: 7029-36.
42. Bonsignori M, Pollara J, Moody MA, et al. Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the VH1 Gene Family. J Virol 2012; 86: 11521-32.
43. Moody MA, Yates NL, Amos JD, et al. HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages. J Virol 2012; 86: 7496-507.
44. Liao HX, Bonsignori M, Alam SM, et al. Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2. Immunity 2013; 38:176-86.
45. Tomaras GD, Ferrari G, Shen, et al. Vaccine induced plasma IgA specific for the C1-region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci USA 2013; 110: 9019-24.
46. Karnasuta C, Paris RM, Cox JH, et al. Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine 2005; 23: 2522-9.
47. Rolland M, Edlefsen PT, Larsen BB, et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 2012; 490: 417-20.
48. Liu P, Yates NL, Shen X, et al. Infectious Virion Capture by HIV-1 gp120 Specific IgG from RV144 Vaccinees. J Virol 2013; 87: 7828-36.
49. Hertz T, Gartland A, Janes H, et al. T-cell based sieve analysis ties HLA A*02 to vaccine efficacy and IgA-C1 immune correlate in RV144 Thai trial: AIDS Vaccine 2012, Boston MA, 9-12 September 2012 [Abstract OA10.05 LB].
50. Karasavvas N, Billings E, Rao M, et al. The Thai phase III HIV-1 vaccine trial (RV144) regimen 1 induces antibodies 2 that target conserved regions within the V2 loop of gp120. AIDS Res Human Retroviruses 2012; 28: 1444-57.
51. Gorny MK, Pan R, Williams C, et al. Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals. Virology 2012; 427: 198-207.
52. Flynn NM, Forthal DN, Harro CD, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191: 654-65.
53. Gilbert PB, Ackers ML, Berman PW, et al. HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine. J Infect Dis 2005; 192: 974-83.
54. Gilbert PB, Peterson ML, Follmann D, et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 2005; 191: 666-77.
55. Gilbert P, Wang M, Wrin T, et al. Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. J Infect Dis 2010; 202: 595-605.
56. Schneider JA, Alam SA, Ackers M, et al. Mucosal HIV-binding antibody and neutralizing activity in high-risk HIV-uninfected female participants in a trial of HIV-vaccine efficacy. J Infect Dis 2007; 196: 1637-44.
57. Forthal DN, Gilbert PB, Landucci G, et al. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol 2007; 178: 6596-603.
58. Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006; 194: 1661-71.
59. WHO/UNAIDS/IAVI International Expert Group. Executive summary and recommendations from the WHO/UNAIDS/IAVI expert group consultation on 'Phase IIB-TOC trials as a novel strategy for evaluation of preventive HIV vaccines', 31 January-2 February 2006, IAVI, New York, USA. AIDS 2007; 21: 539-46.
60. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372: 1881-93.
61. Gray GE, Allen M, Moodie Z, et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis 2011; 11: 507-15.
62. D'Souza MP, Frahm N. Adenovirus 5 serotype vector-specific immunity and HIV-1 infection: a tale of T cells and antibodies. AIDS 2010; 24: 803-9.
63. Duerr A, Huang Y, Buchbinder S, et al. Extended Follow-up Confirms Early Vaccine-Enhanced Risk of HIV Acquisition and Demonstrates Waning Effect Over Time Among Participants in a Randomized Trial of Recombinant Adenovirus HIV Vaccine (Step Study). J Infect Dis 2012; 206: 258-66.
64. Koblin BA, Mayer KH, Noonan E, et al. Sexual Risk Behaviors, Circumcision Status, and Preexisting Immunity to Adenovirus Type 5 Among Men Who Have Sex With Men Participating in a Randomized HIV-1 Vaccine Efficacy Trial: Step Study. J Acquir Immune Defic Syndr 2012; 60: 405-13.
65. Curlin ME, Cassis-Ghavami F, Magaret AS, et al. Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: a case-control study. AIDS 2011; 25: 153-8.
66. Cheng C, Wang L, Gall JG, et al. Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination. PLoS One 2012; 7: e33969.
67. Cohen J. More Woes for Struggling HIV Vaccine Field. Science 2013; 340; 667.
68. McElrath MJ, De Rosa SC, Moodie Z, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008; 372: 1894-905.
69. O'Brien KL, Liu J, King SL, et al. Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat Med 2009; 15: 873-5.
70. Rolland M, Tovanabutra S, deCamp AC, et al. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med 2011; 17: 366-71.
71. Li F, Finnefrock AC, Dubey SA, et al. Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study. PLoS One 2011; 6: e20479.
72. Watkins DI, Burton DR, Kallas EG, et al. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med 2008; 14: 617-21.
73. Reynolds MR, Weiler AM, Piaskowski SM, et al. A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge. Vaccine 2012; 30: 4465-75.
74. Qureshi H, Ma ZM, Huang Y, et al. Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine. J Virol 2012; 86: 2239-50.
75. Walker BD, Ahmed R, Plotkin S. Moving ahead an HIV vaccine: use both arms to beat HIV. Nat Med 2011; 17: 1194-5.
76. Koup RA, Roederer M, Lamoreaux L, et al. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One 2010; 5: e9015.
77. Kibuuka H, Kimutai R, Maboko L, et al. A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172). J Infect Dis 2010; 201: 600-7.
78. Jaoko W, Karita E, Kayitenkore K, et al. Safety and immunogenicity study of multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS One 2010; 5: e12873.
79. Churchyard GJ, Morgan C, Adams E, et al. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One 2011; 6: e21225.
80. Letvin NL, Rao SS, Montefiori DC, et al. Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys. Sci Transl Med 2011; 3: 81ra36.
81. Yamamoto T, Johnson MJ, Price DA, et al. Virus inhibition activity of effector memory CD8(+) T cells determines simian immunodeficiency virus load in vaccinated monkeys after vaccine breakthrough infection. J Virol 2012; 86: 5877-84.
82. Martins MA, Wilson NA, Reed JS, et al. T-cell correlates of vaccine efficacy after a heterologous simian immunodeficiency virus challenge. J Virol 2010; 84: 4352-65.
83. Yang H, Wu H, Hancock G, et al. Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection. J Infect Dis 2012; 206: 552-61.
84. Mascola JR, Haynes BF. HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol Rev 2013; 254: 225-44.
85. Burton DR, Ahmed R, Barouch DH, et al. A Blueprint for HIV Vaccine Discovery. Cell Host Microbe 2012; 12: 396-407.
86. Shukair SA, Allen SA, Cianci GC, et al. Human cervico-vaginal mucus contains an activity that hinders HIV-1 movement. Mucosal Immunol 2013; 6: 427-34.
87. Lai SK, Hida K, Shukair S, et al. Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus. J Virol 2009; 83: 11196-200.
88. Hessell AJ, Hangartner L, Hunter M, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007; 449: 101-4.
89. Forthal DN, Moog C. Fc receptor-mediated antiviral antibodies. Curr Opin HIV AIDS 2009; 4: 388-93.
90. Burton DR, Hessell AJ, Keele BF, et al. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci USA 2011; 108: 11181-6.
91. Arthos J, Cicala C, Martinelli E, et al. HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol 2008; 9: 301-9.
92. Cicala C, Martinelli E, McNally JP, et al. The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci USA 2009; 106: 20877-82.
93. Cicala C, Arthos J, Fauci AS. HIV-1 envelope, integrins and co-receptor use in mucosal transmission of HIV. J Transl Med 2011; 9 Suppl 1: S2.
94. Ansari AA, Reimann KA, Mayne AE, et al. Blocking of α4β7 gut-homing integrin during acute infection leads to decreased plasma and gastrointestinal tissue viral loads in simian immunodeficiency virus-infected rhesus macaques. J Immunol 2011; 186: 1044-59.
95. Nakamura GR, Fonseca DP, O'Rourke SM, et al. Monoclonal antibodies to the V2 domain of MN-rgp120: fine mapping of epitopes and inhibition of α4β7 binding. PLoS One 2012; 7: e39045.
96. Bogers WM, Davis D, Baak I, et al. Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge. Virology 2008; 382: 217-225.
97. Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010; 464: 217-23.
98. Miyake A, Ibuki K, Enose Y, et al. Rapid dissemination of a pathogenic simian/human immunodeficiency virus to systemic organs and active replication in lymphoid tissues following intrarectal infection. J Gen Virol 2006; 87: 1311-20.
99. Belyakov IM, Kuznetsov VA, Kelsall B, et al. Impact of vaccine-induced mucosal high-avidity CD81 CTLs in delay of AIDS viral dissemination from mucosa. Blood 2006; 107: 3258-64.
100. Genesca M, Skinner PJ, Bost KM, et al. Protective attenuated lentivirus immunization induces SIV-specific T cells in the genital tract of rhesus monkeys. Mucosal Immunol 2008; 1: 219-28.
101. Hansen SG, Vieville C, Whizin N, et al. Effector memory T-cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nature Med 2009; 15: 293-9.
102. Zak DE, Aderem A. Overcoming limitations in the systems vaccinology approach: a pathway for accelerated HIV vaccine development. Curr Opin HIV AIDS 2012; 7: 58-63.
103. Haddad EK, Pantaleo G. Systems biology in the development of HIV vaccines. Curr Opin HIV AIDS 2012; 7: 44-9.
104. Querec TD, Akondy RS, Lee EK, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 2009; 10: 116-25.
105. Nakaya HI, Wrammert J, Lee EK, et al. Systems biology of vaccination for seasonal influenza in humans. Nat Immunol 2011; 12: 786-95.
106. Pido-Lopez J, Wang Y, Seidl T, et al. The effect of allogeneic in vitro stimulation and in vivo immunization on memory CD4(+) T-cell APOBEC3G expression and HIV-1 infectivity. Eur J Immunol 2009; 39: 1956-65.
107. Jin X, Wu H, Smith H. APOBEC3G levels predict rates of progression to AIDS. Retrovirology 2007; 4: 20.
108. Biasin M, Clerici M, Piacentini L. Innate immunity in resistance to HIV infection. J Infect Dis 2010; 202 Suppl 3: S361-5.
109. Wang Y, Bergmeier LA, Stebbings R, et al. Mucosal immunization in macaques upregulates the innate APOBEC 3G anti-viral factor in CD4(+) memory T cells. Vaccine 2009; 27: 870-81.
110. Sui Y, Zhu Q, Gagnon S, et al. Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques. Proc Natl Acad Sci USA 2010; 107: 9843-8.
111. Wang Y, Whittall T, Rahman D, et al. The role of innate APOBEC3G and adaptive AID immune responses in HLA-HIV/SIV immunized SHIV infected macaques. PLoS One 2012; 7: e34433.
112. Morgan C, Marthas M, Miller C, et al. The use of nonhuman primate models in HIV vaccine development. PLoS Med 2008; 5: e173.
113. Vaccari M, Poonam P, Franchini G. Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV. Expert Rev Vaccines 2010; 9: 997-1005.
114. Franchini G, Pegu P, Gordon S, et al. Antibodies to the envelope protein protect macaques from SIVmac251 acquisition in an immunization regimen that mimics the RV144 Thai trial. AIDS Vaccine 2012, Boston MA, 9-12 September 2012 [Abstract OA01.02].
115. Liyanage NP, Pegu P, Gordon S, et al. RV144-like trial in macaques using ALVAC-SIV & gp120 induces innate immunity and increases the frequency of NK22 & NKG2A+ cells in mucosal tissues. AIDS Vaccine 2012, Boston MA, 9-12 September 2012 [Abstract OA03.02].
116. Keele BF, Li H, Learn GH, et al. Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med 2009; 206: 1117-34.
117. Sina S, Tovanabutra S, Sanders-Buell E, et al. Evidence for Env-V2 sieve effect in breakthrough SIV infections in rhesus macaques vaccinated with Ad26/MVA and MVA/Ad26 constructs. AIDS Vaccine 2012, Boston MA, 9-12 September 2012 [Abstract OA06.04].
118. Freel SA, Saunders KO, Tomaras GD. CD8(+) T-cell-mediated control of HIV-1 and SIV infection. Immunol Res 2011; 49: 135-46.
119. McDermott AB, Koup RA. CD8+ T cells in preventing HIV infection and disease. AIDS 2012; 26: 1281-92.
120. Winstone N, Wilson AJ, Morrow G, et al. Enhanced control of pathogenic Simian immunodeficiency virus SIVmac239 replication in macaques immunized with an interleukin-12 plasmid and a DNA prime-viral vector boost vaccine regimen. J Virol 2011; 85: 9578-87.
121. Liu J, O'Brien KL, Lynch DM, et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2009; 457: 87-91.
122. Li H, Liu J, Carville A, et al. Durable mucosal simian immunodeficiency virus-specific effector memory T lymphocyte responses elicited by recombinant adenovirus vectors in rhesus monkeys. J Virol 2011; 85: 11007-15.
123. Mudd PA, Martins MA, Ericsen AJ, et al. Vaccine-induced CD8+ T cells control AIDS virus replication. Nature 2012; 491: 129-33.
124. Hansen SG, Ford JC, Lewis MS, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011; 473: 523-7.
125. Hansen SG, Sacha JB, Hughes CM, et al. Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science 2013; 340: 1237874.
126. Goonetilleke N, McMichael AJ. Immunology. Antigen processing takes a new direction. Science 2013; 340: 937-8.
127. Bett AJ, Dubey SA, Mehrotra DV, et al. Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans. Vaccine 2010; 28: 7881-9.
128. Esparza J. Solid vaccine protection against SIV in rhesus monkeys provides proof-of-concept for further evaluation of a novel HIV vaccine approach in humans. Expert Rev Vaccines 2012; 11: 539-42.
129. Gorse GJ, Patel GB, Mandava M, et al. MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group. AIDS Res Hum Retroviruses 1999; 15: 921-30.
130. Banerjee K, Klasse PJ, Sanders RW, et al. IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines. AIDS Res Hum Retroviruses 2010; 26: 445-58.
131. Roussilhon C, Oeuvray C, Müller-Graf C, et al. Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. PLoS Med 2007; 4: e320.
132. Kam YW, Simarmata D, Chow A, et al. Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long-term clinical protection. J Infect Dis 2012; 205: 1147-54.
133. Dugast AS, Tonelli A, Berger CT, et al. Decreased Fc receptor expression on innate immune cells is associated with impaired antibody-mediated cellular phagocytic activity in chronically HIV-1 infected individuals. Virology 2011; 415: 160-7.
134. Crotty S. Follicular Helper CD4 T Cells (TFH). Annu Rev Immunol 2011; 29: 621-63.
135. Fukazawa Y, Park H, Cameron MJ, et al. Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines. Nat Med 2012; 18: 1673-81.
136. Alpert MD, Harvey JD, Lauer WA, et al. ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge. PLoS Pathog 2012; 8: e1002890.
137. Fuchs JD, Morgan C, Bart P, et al. DNA and recombinant adenovirus serotype 35 and 5 preventive HIV-1 vaccines with Env A inserts elicit cross-clade binding and V1V2 antibodies. AIDS Vaccine 2012, Boston MA, 9-12 September 2012 [Abstract P04.29 LB].
138. Pinter A, Honnen WJ, Kayman SC, et al. Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120. Vaccine 1998; 16: 1803-11.